TITLE:
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)

CONDITION:
Chronic Lymphocytic Leukemia

INTERVENTION:
IDEC-152

SUMMARY:

      To determine what side effects and what clinical effects if any the administration of this
      investigational product, IDEC-152 (an antibody against CD23 which is an important protein on
      leukemia cells and certain cells in the body's immune system), has on the CLL patient
      population.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Signed IRB-approved informed consent.

          -  Greater than 18 years of age

          -  Proof of CD23+ CLL or small lymphocytic lymphoma (SLL)

          -  Progressive disease after at least 1 course of chemotherapy

          -  Acceptable hematologic status, liver function, renal function, and pulmonary function

          -  Patients of reproductive potential must agree to follow accepted birth control
             methods during treatment and for 3 months after completion of treatment

        Exclusion Criteria:

          -  Previous exposure to IDEC-152 or other anti-CD23 antibodies

          -  Presence of HIV infection or AIDS

          -  Serious nonmalignant disease

          -  Active uncontrolled bacterial, viral or fungal infections.

          -  Clinically active autoimmune disease

          -  Pregnant or currently breast feeding
      
